Spotlight Pathology, a spinout from the University of Manchester, has secured a new investment of £1.4m to accelerate the commercial rollout of its AI cancer diagnostics product.
Spotlight Pathology is developing AI-powered tools for diagnosing blood cancer.
The firm has picked up a few investments over the past few years, including £425,000 raised in May last year and £125,000 raised the year before.
Now the company is quickly working towards the commercial release of its flagship product, a lymphoma diagnostic device powered by AI.
The first deployments of the device in NHS sites are expected later this year.
“This investment comes at a critical and exciting time in Spotlight’s development, as we transition our primary focus from tech development to supporting our products in clinical use,” said Sam Perona, chief executive of Spotlight Pathology.
The funding round was co-led by Liverpool City Region Seed Fund and UKI2S with additional support from Deepbridge, Lyva Labs, EHE Ventures and River Capital.
The company is based in Sci-Tech Daresbury, a major science park and innovation campus.
John Leake, business growth director at Sci-Tech Daresbury said: “We’re delighted to see this significant and strategic investment into Spotlight Pathology. We’ve worked with the company from their time as one of our Future Club businesses in 2023 and it has been great to see their development and growth.
“Spotlight Pathology bring together two key areas that are important for Sci-Tech Daresbury, the development and application of AI technology, alongside delivering innovation into the healthcare sector. We look forward to seeing further continued success for the business.”
